IRVINE, Calif.--(BUSINESS WIRE)--

California Stem Cell, Inc. (CSC)s Hans S. Keirstead, Ph.D. will speak at todays Global Emerging Leaders Forum in New York City, participating in a panel of the worlds leading innovators, philanthropists, and business thought-leaders who have gathered to discuss global issues. This symposium is the latest in a series of thought leadership and panel discussion appearances by CSC team members in recent months.

The NYC-based Global Emerging Leadership Forum was founded in 2011 to support emerging professionals through the discussion of the top social and economic issues of today, as well as emerging trends of the future. Dr. Keirstead will speak at 1pm in New York Citys Kaufmann Concert Hall, joining a diverse panel of influential and forward-thinking leaders in their respective fields. Attendees will gain valuable insight into the future of global society, global citizenship, corporate responsibility, and the politics of being an emerging global leader.

In February of this year, Dr. Keirstead presented at Singularity Universitys FutureMed event Exploring the Future of Healthcare. He delivered a presentation highlighting the powerful potential uses of stem cells for spinal cord injury and beyond. More recently, California Stem Cells Gabriel Nistor, M.D. participated in an Institute of Medicine (IOM) hosted review of the California Institute of Regenerative Medicine (CIRM)s programs, operations, strategies, and performance.

Details of California Stem Cell pubic speaking appearances are at: http://californiastemcell.com/press_cal

More information about the Global Emerging Leadership Forum: http://www.emergingleadersnyc.com/

More information about FutureMed: http://futuremed2020.com/

About California Stem Cell

California Stem Cell Inc. (CSC) is an Irvine, CA based company with proprietary methods to generate human stem cell lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and GMP processes. CSC is able to supply its human cell populations to companies and institutions worldwide for use in the development of therapies, efficacy screening or the creation of toxicity profiles for candidate drugs, and experimental research tools.

CSC is currently focused on the development of stem cell based therapies for spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS, or Lou Gehrigs Disease), and metastatic cancers.

View original post here:
California Stem Cell Chairman Hans Keirstead Speaks at Prominent Global Emerging Leadership Forum